Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study
Z Zhou, H Zheng, G Xiao, X Xie, J Rang… - BMC Infectious …, 2024 - Springer
Background Azvudine has clinical benefits and acceptable safety against COVID-19,
including in patients with comorbidities, but there is a lack of available data for its use in …
including in patients with comorbidities, but there is a lack of available data for its use in …
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action
Y Liang, X Quan, R Gu, Z Meng, H Gan, Z Wu, Y Sun… - Heliyon, 2024 - cell.com
Following the coronavirus disease-2019 outbreak caused by severe acute respiratory
syndrome coronavirus type 2 (SARS-CoV-2), there is an ongoing need to seek drugs that …
syndrome coronavirus type 2 (SARS-CoV-2), there is an ongoing need to seek drugs that …
Risk factors and prognosis for coronavirus disease 2019 among 131 hemodialysis patients during the Omicron variant epidemic
W Wen, S Cai, Y Li, X Wu - Renal Failure, 2023 - Taylor & Francis
The present study evaluated the presentations and outcomes of coronavirus disease 2019
(COVID-19) among patients undergoing maintenance hemodialysis (MHD) and the impact …
(COVID-19) among patients undergoing maintenance hemodialysis (MHD) and the impact …
Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective …
J Xu, J Li, M Chen, H Jiang, X Fan, Y Hu… - Expert Review of …, 2024 - Taylor & Francis
Background This study aimed to establish population pharmacokinetics (PPK) models of
nirmatrelvir/ritonavir in critically ill Chinese patients with the coronavirus disease 2019 …
nirmatrelvir/ritonavir in critically ill Chinese patients with the coronavirus disease 2019 …
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
MP Chen, DX Jiang, JX Rang, HB Zhuo, ZG Zhou - Scientific Reports, 2024 - nature.com
This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir,
and molnupiravir in adult patients with mild-to-moderate COVID-19. This retrospective cohort …
and molnupiravir in adult patients with mild-to-moderate COVID-19. This retrospective cohort …
The pharmacists' interventions after a Drug and Therapeutics Committee (DTC) establishment during the COVID-19 pandemic
AB Kassem, AZ Al Meslamani… - … Policy and Practice, 2024 - Taylor & Francis
Introduction Healthcare systems in developing countries faced significant challenges during
COVID-19, grappling with limited resources and staffing shortages. Assessment of the …
COVID-19, grappling with limited resources and staffing shortages. Assessment of the …
Population Pharmacokinetics of Nirmatrelvir in Chinese Patients with COVID-19: Therapeutic Drug Monitoring and Dosing Regimen Selection in Clinical Practice
P Yang, W Liu, Y Ying, L Zhao, X Xiong, X Zhang… - International Journal of …, 2024 - Elsevier
ABSTRACT OBJECTIVES To establish a population pharmacokinetics (PopPK) model of
nirmatrelvir in Chinese COVID-19 patients and provide reference for refining the dosing …
nirmatrelvir in Chinese COVID-19 patients and provide reference for refining the dosing …
Kidney Issues Associated with COVID-19 Disease
P Dousdampanis, A Mouzaki, K Trigka, I Stefanidis… - Encyclopedia, 2023 - mdpi.com
Definition Infection with SARS-CoV-2 and the resulting COVID-19 can cause both lung and
kidney damage. SARS-CoV-2 can directly infect renal cells expressing ACE2 receptors …
kidney damage. SARS-CoV-2 can directly infect renal cells expressing ACE2 receptors …
Effectiveness and Optimal Timing of Azvudine in COVID-19 Patients: A Multi-center Retrospective Study in Beijing, China
X Han, X Han, Y Wang, Z Wang, J Cui, W Zhao, G Mo… - 2023 - researchsquare.com
Background: Clinical effectiveness of Azvudine against coronavirus infection and optimal
time for initiation of Azvudine treatment to hospitalized COVID-19 patients are not fully …
time for initiation of Azvudine treatment to hospitalized COVID-19 patients are not fully …
Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients
X Xu, H Zhang, L Liu, Q Fu, C Wu, X Lin, K Tang… - European Journal of …, 2024 - Springer
Objectives To describe the pharmacokinetic (PK) characteristics of nirmatrelvir/ritonavir in
renal transplant recipients and explore the potential factors that related to the PK variance of …
renal transplant recipients and explore the potential factors that related to the PK variance of …